FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301398107> ?p ?o ?g. }

• W4301398107 endingPage "108" @default.
• W4301398107 startingPage "100" @default.
• W4301398107 abstract "Neoadjuvant chemotherapy (NAC) is widely used to treat borderline resectable pancreatic cancer. This study aimed to evaluate the serum carbohydrate antigen (CA)19-9 response, in association with survival, after four cycles of NAC-gemcitabine plus nab-paclitaxel.From 2015 to 2018, patients with borderline resectable pancreatic cancer were treated with NAC. Patients were stratified into two groups after excluding CA19-9 non-secretor: Group L (CA19-9 ≥2 and ≤500 U/mL) and Group H (CA19-9 >500 U/mL). The CA19-9 decrease during NAC was evaluated as a response of NAC and was assessed in association with survival concomitant with other prognosis factors.Eighty-seven patients were evaluated (Group L: n = 43, Group H: n = 44). In intention-to-treat-based analysis, Group L exhibited significantly better progression-free survival (PFS) than Group H (median PFS: 24 vs 14months). In resection cohort, no correlation was detected between the CA19-9 decrease and survival in Group L. In Group H, the CA19-9 decrease ≤80% was associated with unfavorable survival in multivariate analysis [Hazard ratio: 4.738 (P = 0.007)].In patients with pre-treatment CA19-9 >500 U/mL, the CA19-9 decrease ≤80% was strongly associated with poor survival and new strategy should be reconsidered for these patients." @default.
• W4301398107 created "2022-10-05" @default.
• W4301398107 creator A5010030251 @default.
• W4301398107 creator A5010319344 @default.
• W4301398107 creator A5020929588 @default.
• W4301398107 creator A5026341464 @default.
• W4301398107 creator A5030164112 @default.
• W4301398107 creator A5032295043 @default.
• W4301398107 creator A5033050593 @default.
• W4301398107 creator A5033354878 @default.
• W4301398107 creator A5043441615 @default.
• W4301398107 creator A5046032024 @default.
• W4301398107 creator A5050881417 @default.
• W4301398107 creator A5070620598 @default.
• W4301398107 creator A5075220614 @default.
• W4301398107 date "2023-01-01" @default.
• W4301398107 modified "2023-10-16" @default.
• W4301398107 title "Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels" @default.
• W4301398107 cites W1968431211 @default.
• W4301398107 cites W2008014332 @default.
• W4301398107 cites W2012005360 @default.
• W4301398107 cites W2019607817 @default.
• W4301398107 cites W2044211072 @default.
• W4301398107 cites W2050643752 @default.
• W4301398107 cites W2079934168 @default.
• W4301398107 cites W2096998881 @default.
• W4301398107 cites W2123169628 @default.
• W4301398107 cites W2152811869 @default.
• W4301398107 cites W2165480504 @default.
• W4301398107 cites W2343177790 @default.
• W4301398107 cites W2344938325 @default.
• W4301398107 cites W2412717755 @default.
• W4301398107 cites W2467479187 @default.
• W4301398107 cites W2549878845 @default.
• W4301398107 cites W2557297120 @default.
• W4301398107 cites W2573380080 @default.
• W4301398107 cites W2770835903 @default.
• W4301398107 cites W2804908082 @default.
• W4301398107 cites W2810100652 @default.
• W4301398107 cites W2896593342 @default.
• W4301398107 cites W2897709693 @default.
• W4301398107 cites W2921399058 @default.
• W4301398107 cites W2926499479 @default.
• W4301398107 cites W2934191883 @default.
• W4301398107 cites W2998438819 @default.
• W4301398107 cites W3003386935 @default.
• W4301398107 cites W3007158114 @default.
• W4301398107 cites W3015954630 @default.
• W4301398107 cites W3032914447 @default.
• W4301398107 cites W3092945245 @default.
• W4301398107 cites W3112747790 @default.
• W4301398107 cites W3135189210 @default.
• W4301398107 cites W3153075376 @default.
• W4301398107 doi "https://doi.org/10.1016/j.hpb.2022.09.012" @default.
• W4301398107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36280425" @default.
• W4301398107 hasPublicationYear "2023" @default.
• W4301398107 type Work @default.
• W4301398107 citedByCount "1" @default.
• W4301398107 countsByYear W43013981072023 @default.
• W4301398107 crossrefType "journal-article" @default.
• W4301398107 hasAuthorship W4301398107A5010030251 @default.
• W4301398107 hasAuthorship W4301398107A5010319344 @default.
• W4301398107 hasAuthorship W4301398107A5020929588 @default.
• W4301398107 hasAuthorship W4301398107A5026341464 @default.
• W4301398107 hasAuthorship W4301398107A5030164112 @default.
• W4301398107 hasAuthorship W4301398107A5032295043 @default.
• W4301398107 hasAuthorship W4301398107A5033050593 @default.
• W4301398107 hasAuthorship W4301398107A5033354878 @default.
• W4301398107 hasAuthorship W4301398107A5043441615 @default.
• W4301398107 hasAuthorship W4301398107A5046032024 @default.
• W4301398107 hasAuthorship W4301398107A5050881417 @default.
• W4301398107 hasAuthorship W4301398107A5070620598 @default.
• W4301398107 hasAuthorship W4301398107A5075220614 @default.
• W4301398107 hasConcept C121608353 @default.
• W4301398107 hasConcept C126322002 @default.
• W4301398107 hasConcept C143998085 @default.
• W4301398107 hasConcept C144369459 @default.
• W4301398107 hasConcept C207103383 @default.
• W4301398107 hasConcept C2776694085 @default.
• W4301398107 hasConcept C2779384505 @default.
• W4301398107 hasConcept C2780210213 @default.
• W4301398107 hasConcept C2780258809 @default.
• W4301398107 hasConcept C38180746 @default.
• W4301398107 hasConcept C44249647 @default.
• W4301398107 hasConcept C71924100 @default.
• W4301398107 hasConcept C90924648 @default.
• W4301398107 hasConceptScore W4301398107C121608353 @default.
• W4301398107 hasConceptScore W4301398107C126322002 @default.
• W4301398107 hasConceptScore W4301398107C143998085 @default.
• W4301398107 hasConceptScore W4301398107C144369459 @default.
• W4301398107 hasConceptScore W4301398107C207103383 @default.
• W4301398107 hasConceptScore W4301398107C2776694085 @default.
• W4301398107 hasConceptScore W4301398107C2779384505 @default.
• W4301398107 hasConceptScore W4301398107C2780210213 @default.
• W4301398107 hasConceptScore W4301398107C2780258809 @default.
• W4301398107 hasConceptScore W4301398107C38180746 @default.
• W4301398107 hasConceptScore W4301398107C44249647 @default.
• W4301398107 hasConceptScore W4301398107C71924100 @default.

• next